UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
28.58
-0.20 (-0.69%)
At close: May 18, 2026, 4:00 PM EDT
28.60
+0.02 (0.07%)
Pre-market: May 19, 2026, 6:27 AM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $50.96M in the quarter ending March 31, 2026, with 151.60% growth. This brings the company's revenue in the last twelve months to $140.49M, up 52.92% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth.
Revenue (ttm)
$140.49M
Revenue Growth
+52.92%
P/S Ratio
9.91
Revenue / Employee
$471,453
Employees
298
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Immunocore Holdings | 412.81M |
| KalVista Pharmaceuticals | 114.48M |
| Vir Biotechnology | 65.50M |
| Immatics | 43.00M |
| Maze Therapeutics | 20.00M |
| AtaiBeckley | 3.49M |
URGN News
- 3 days ago - UroGen Pharma reports month results from UTOPIA trial - TheFly
- 3 days ago - UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - GlobeNewsWire
- 5 days ago - UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 days ago - UroGen Pharma presents 36-month ENVISION trial data - TheFly
- 5 days ago - ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial - GlobeNewsWire
- 7 days ago - UroGen Pharma assumed with a Buy at Ladenburg - TheFly
- 8 days ago - UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright - TheFly
- 11 days ago - UroGen Pharma price target raised to $40 from $34 at Oppenheimer - TheFly